Merck & Co., Inc. (MRK)

131,20 +0,48 (+0,37 %) À la clôture : 04:00PM EDT

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 70 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Robert M. Davis J.D.	Chairman, President & CEO	5,57M	8,44M	1967
Ms. Caroline Litchfield	Executive VP & CFO	3,09M	S.O.	1969
Mr. Richard R. DeLuca Jr.	Executive VP & President of Merck Animal Health	2,4M	8,03M	1963
Mr. Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	2,49M	12,49M	1960
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories	3,61M	S.O.	1963
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller	S.O.	S.O.	1967
Mr. David Michael Williams	Executive VP and Chief Information & Digital Officer	S.O.	S.O.	1969
Mr. Peter Dannenbaum	Vice President of Investor Relations	S.O.	S.O.	S.O.
Ms. Jennifer L. Zachary	Executive VP & General Counsel	2,73M	3,46M	1978
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	S.O.	S.O.	1982

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merck & Co., Inc. en date du 1 avril 2024 est 4. Les scores principaux sont Audit : 6; Société : 5; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.